New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

Journal of Hepatology

Volumn 62, Issue S1, 2015, Pages S25-S37

  Beuers, Ulrich ^a   Trauner, Michael ^b   Jansen, Peter ^a   Poupon, Raoul ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cholestasis; FXR; PXR; UDCA

Indexed keywords

CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; URSODEOXYCHOLIC ACID; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CELL RECEPTOR; COTRANSPORTER; FARNESOID X-ACTIVATED RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER; STEROID RECEPTOR;

BILE DUCT DISEASE; CHOLESTASIS; DISEASE COURSE; DRUG MECHANISM; ENERGY METABOLISM; GENE EXPRESSION; HUMAN; IN VITRO STUDY; INTRAHEPATIC CHOLESTASIS; LIVER CELL; PHAGOCYTOSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHOLESTASIS, INTRAHEPATIC;

ANIMALS; CHOLESTASIS, INTRAHEPATIC; HUMANS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PPAR ALPHA; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, STEROID; SYMPORTERS; URSODEOXYCHOLIC ACID;

EID: 84942878841     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.023     Document Type: Review

References (200)

1. U. Beuers, and J.L. Boyer Bile - A historical review of studies on its form and function J.B. Kirsner, Gastroenterology in the 20th century 1994 Lea & Ferbiger New York 267 288
2. M. Trauner, P.J. Meier, and J.L. Boyer Molecular pathogenesis of cholestasis N Engl J Med 339 1998 1217 1227
3. L.J. Maillette de Buy Wenniger, R.P. Oude Elferink, and U. Beuers Molecular targets for the treatment of fibrosing cholangiopathies Clin Pharmacol Ther 92 2012 381 387
4. G. Zollner, and M. Trauner Nuclear receptors as therapeutic targets in cholestatic liver diseases Br J Pharmacol 156 2009 7 27
5. A.F. Hofmann, and A. Roda Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem J Lipid Res 25 1984 1477 1489
6. I. Makino, K. Shinozaki, K. Yoshino, and S. Nakagawa Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid Nippon Shokakibyo Gakkai Zasshi 72 1975 690 702
7. R. Poupon, Y. Chretien, R.E. Poupon, F. Ballet, Y. Calmus, and F. Darnis Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1 1987 834 836
8. U. Leuschner, H. Fischer, W. Kurtz, S. Guldutuna, K. Hubner, A. Hellstern, and et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial Gastroenterology 97 1989 1268 1274
9. R.E. Poupon, B. Balkau, E. Eschwege, and R. Poupon A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group N Engl J Med 324 1991 1548 1554
10. R.E. Poupon, B. Balkau, J. Guechot, and F. Heintzmann Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue Hepatology 19 1994 635 640
11. R.E. Poupon, K.D. Lindor, K. Cauch-Dudek, E.R. Dickson, R. Poupon, and E.J. Heathcote Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis Gastroenterology 113 1997 884 890
12. R.E. Poupon, R. Poupon, and B. Balkau Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group N Engl J Med 330 1994 1342 1347
13. R.E. Poupon, A.M. Bonnand, Y. Chretien, and R. Poupon Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group Hepatology 29 1999 1668 1671
14. A. Pares, L. Caballeria, J. Rodes, M. Bruguera, L. Rodrigo, A. Garcia-Plaza, and et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver J Hepatol 32 2000 561 566
15. K.D. Lindor, M.E. Gershwin, R. Poupon, M. Kaplan, N.V. Bergasa, and E.J. Heathcote Primary biliary cirrhosis Hepatology 50 2009 291 308
16. EASL Clinical Practice Guidelines: management of cholestatic liver diseases J Hepatol 51 2009 237 267
17. C. Corpechot, F. Carrat, A. Bahr, Y. Chretien, R.E. Poupon, and R. Poupon The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis Gastroenterology 128 2005 297 303
18. W.J. Lammers, H.R. van Buuren, G.M. Hirschfield, H.L. Janssen, P. Invernizzi, A.L. Mason, and et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study Gastroenterology 147 2014 1338 1349
19. A. Pares, L. Caballeria, and J. Rodes Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid Gastroenterology 130 2006 715 720
20. C. Corpechot, L. Abenavoli, N. Rabahi, Y. Chretien, T. Andreani, C. Johanet, and et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 2008 871 877
21. E.M. Kuiper, B.E. Hansen, R.A. de Vries, J.W. den Ouden-Muller, T.J. van Ditzhuijsen, E.B. Haagsma, and et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid Gastroenterology 136 2009 1281 1287
22. R. Poupon Primary biliary cirrhosis: a 2010 update J Hepatol 52 2010 745 758
23. U. Beuers, and K.D. Lindor A major step towards effective treatment evaluation in primary biliary cirrhosis J Hepatol 55 2011 1178 1180
24. J. Shi, Z. Li, X. Zeng, Y. Lin, and W.F. Xie Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials Hepatol Res 39 2009 865 873
25. G. Poropat, V. Giljaca, D. Stimac, and C. Gluud Bile acids for primary sclerosing cholangitis Cochrane Database Syst Rev 2011 CD003626
26. K.D. Lindor, K.V. Kowdley, V.A. Luketic, M.E. Harrison, T. McCashland, A.S. Befeler, and et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 2009 808 814
27. R. Chapman, J. Fevery, A. Kalloo, D.M. Nagorney, K.M. Boberg, B. Shneider, and et al. Diagnosis and management of primary sclerosing cholangitis Hepatology 51 2010 660 678
28. U. Beuers Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis Nat Clin Pract Gastroenterol Hepatol 3 2006 318 328
29. K. Dilger, S. Hohenester, U. Winkler-Budenhofer, B.A. Bastiaansen, F.G. Schaap, C. Rust, and et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health J Hepatol 57 2012 133 140
30. K. Kitani Hepatoprotective effect of ursodeoxycholate in experimental animals G. Paumgartner, Strategies for the treatment of hepatobiliary diseases 1990 Kluwer Lancaster 44 56
31. B. Bouscarel, H. Fromm, and R. Nussbaum Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes Am J Physiol 264 1993 G243 251
32. U. Beuers, M.H. Nathanson, and J.L. Boyer Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes Gastroenterology 104 1993 604 612
33. U. Beuers, M.H. Nathanson, C.M. Isales, and J.L. Boyer Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis J Clin Invest 92 1993 2984 2993
34. U. Beuers, M. Thiel, H. Bardenheuer, and G. Paumgartner Tauroursodeoxycholic acid inhibits the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine Biochem Biophys Res Commun 171 1990 1115 1121
35. B. Bouscarel, T.W. Gettys, H. Fromm, and H. Dubner Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC Am J Physiol 268 1995 G300 G310
36. U. Beuers, D.C. Throckmorton, M.S. Anderson, C.M. Isales, W. Thasler, G.A. Kullak-Ublick, and et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes Gastroenterology 110 1996 1553 1563
37. R.T. Stravitz, Y.P. Rao, Z.R. Vlahcevic, E.C. Gurley, W.D. Jarvis, and P.B. Hylemon Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 alpha-hydroxylase Am J Physiol 271 1996 G293 G303
38. F. Schliess, A.K. Kurz, S. vom Dahl, and D. Haussinger Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver Gastroenterology 113 1997 1306 1314
39. A.K. Kurz, D. Graf, M. Schmitt, S. Vom Dahl, and D. Haussinger Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats Gastroenterology 121 2001 407 419
40. D. Haussinger, A.K. Kurz, M. Wettstein, D. Graf, S. Vom Dahl, and F. Schliess Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis Gastroenterology 124 2003 1476 1487
41. H. Gohlke, B. Schmitz, A. Sommerfeld, R. Reinehr, and D. Haussinger Alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes Hepatology 57 2013 1117 1129
42. D. Haussinger, N. Saha, C. Hallbrucker, F. Lang, and W. Gerok Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver Biochem J 291 1993 355 360
43. M. Marzioni, H. Francis, A. Benedetti, Y. Ueno, G. Fava, J. Venter, and et al. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts Am J Pathol 168 2006 398 409
44. U. Beuers, M. Bilzer, A. Chittattu, G.A. Kullak-Ublick, D. Keppler, G. Paumgartner, and et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver Hepatology 33 2001 1206 1216
45. R. Wimmer, S. Hohenester, T. Pusl, G.U. Denk, C. Rust, and U. Beuers Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver Gut 57 2008 1448 1454
46. L.N. Cruz, M.T. Guerra, E. Kruglov, A. Mennone, C.R. Garcia, J. Chen, and et al. Regulation of multidrug resistance-associated protein 2 by calcium signaling in mouse liver Hepatology 52 2010 327 337
47. - umbrella Hepatology 52 2010 1489 1496
48. - umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes Hepatology 55 2012 173 183
49. J. Prieto, N. Garcia, J.M. Marti-Climent, I. Penuelas, J.A. Richter, and J.F. Medina Assessment of biliary bicarbonate secretion in humans by positron emission tomography Gastroenterology 117 1999 167 172
50. J. Prieto, C. Qian, N. Garcia, J. Diez, and J.F. Medina Abnormal expression of anion exchanger genes in primary biliary cirrhosis Gastroenterology 105 1993 572 578
51. J.F. Medina, A. Martinez, J.J. Vazquez, and J. Prieto Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis Hepatology 25 1997 12 17
52. U. Beuers, U. Spengler, F.M. Zwiebel, J. Pauletzki, S. Fischer, and G. Paumgartner Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease Hepatology 15 1992 603 608
53. H.U. Marschall, M. Wagner, G. Zollner, P. Fickert, U. Diczfalusy, J. Gumhold, and et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans Gastroenterology 129 2005 476 485
54. C. Benz, S. Angermuller, U. Tox, P. Kloters-Plachky, H.D. Riedel, P. Sauer, and et al. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes J Hepatol 28 1998 99 106
55. K.N. Lazaridis, G.J. Gores, and K.D. Lindor Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' J Hepatol 35 2001 134 146
56. C.M. Rodrigues, G. Fan, X. Ma, B.T. Kren, and C.J. Steer A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation J Clin Invest 101 1998 2790 2799
57. H. Tanaka, and I. Makino Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor Biochem Biophys Res Commun 188 1992 942 948
58. T. Miura, R. Ouchida, N. Yoshikawa, K. Okamoto, Y. Makino, T. Nakamura, and et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid J Biol Chem 276 2001 47371 47378
59. T. Takigawa, H. Miyazaki, M. Kinoshita, N. Kawarabayashi, K. Nishiyama, K. Hatsuse, and et al. Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice Am J Physiol Gastrointest Liver Physiol 305 2013 G427 438
60. H. Tanaka, Y. Makino, T. Miura, F. Hirano, K. Okamoto, K. Komura, and et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway J Immunol 156 1996 1601 1608
61. S. Sola, J.D. Amaral, R.E. Castro, R.M. Ramalho, P.M. Borralho, B.T. Kren, and et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes Hepatology 42 2005 925 934
62. A.F. Hofmann, and L.R. Hagey Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades J Lipid Res 55 2014 1553 1595
63. A.F. Hofmann, S.F. Zakko, M. Lira, C. Clerici, L.R. Hagey, K.K. Lambert, and et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans Hepatology 42 2005 1391 1398
64. H.Z. Yeh, C.D. Schteingart, L.R. Hagey, H.T. Ton-Nu, U. Bolder, M.A. Gavrilkina, and et al. Effect of side chain length on biotransformation, hepatic transport, and choleretic properties of chenodeoxycholyl homologues in the rodent: studies with dinorchenodeoxycholic acid, norchenodeoxycholic acid, and chenodeoxycholic acid Hepatology 26 1997 374 385
65. Y.B. Yoon, L.R. Hagey, A.F. Hofmann, D. Gurantz, E.L. Michelotti, and J.H. Steinbach Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents Gastroenterology 90 1986 837 852
66. M. Dumont, S. Erlinger, and S. Uchman Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport Gastroenterology 79 1980 82 89
67. M. Trauner, P. Fickert, E. Halilbasic, and T. Moustafa Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases Wien Med Wochenschr 158 2008 542 548
68. P. Fickert, M. Wagner, H.U. Marschall, A. Fuchsbichler, G. Zollner, O. Tsybrovskyy, and et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice Gastroenterology 130 2006 465 481
69. E. Halilbasic, R. Fiorotto, P. Fickert, H.U. Marschall, T. Moustafa, C. Spirli, and et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice Hepatology 49 2009 1972 1981
70. P. Fickert, M.J. Pollheimer, D. Silbert, T. Moustafa, E. Halilbasic, E. Krones, and et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice J Hepatol 58 2013 1201 1208
71. T. Moustafa, P. Fickert, C. Magnes, C. Guelly, A. Thueringer, S. Frank, and et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury Gastroenterology 142 2012 e112
72. G.U. Denk, S. Maitz, R. Wimmer, C. Rust, P. Invernizzi, S. Ferdinandusse, and et al. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver Hepatology 52 2010 1758 1768
73. M. Trauner, E. Halilbasic, L. Kazemi-Shirazi, C. Kienbacher, K. Staufer, S. Traussnigg, and et al. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies Dig Dis 32 2014 631 636
74. M. Trauner, P. Fickert, and M. Wagner MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes Semin Liver Dis 27 2007 77 98
75. B.M. Forman, E. Goode, J. Chen, A.E. Oro, D.J. Bradley, T. Perlmann, and et al. Identification of a nuclear receptor that is activated by farnesol metabolites Cell 81 1995 687 693
76. W. Seol, H.S. Choi, and D.D. Moore Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors Mol Endocrinol 9 1995 72 85
77. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A. Luk, and et al. Identification of a nuclear receptor for bile acids Science 284 1999 1362 1365
78. M. Baes, T. Gulick, H.S. Choi, M.G. Martinoli, D. Simha, and D.D. Moore A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements Mol Cell Biol 14 1994 1544 1552
79. M. Makishima, T.T. Lu, W. Xie, G.K. Whitfield, H. Domoto, R.M. Evans, and et al. Vitamin D receptor as an intestinal bile acid sensor Science 296 2002 1313 1316
80. S.M. Houten, M. Watanabe, and J. Auwerx Endocrine functions of bile acids EMBO J 25 2006 1419 1425
81. G. Le Martelot, T. Claudel, D. Gatfield, O. Schaad, B. Kornmann, G. Lo Sasso, and et al. REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis PLoS Biol 7 2009 e1000181
82. H. Duez, J.N. van der Veen, C. Duhem, B. Pourcet, T. Touvier, C. Fontaine, and et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha Gastroenterology 135 2008 689 698
83. H. Wang, J. Chen, K. Hollister, L.C. Sowers, and B.M. Forman Endogenous bile acids are ligands for the nuclear receptor FXR/BAR Mol Cell 3 1999 543 553
84. B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, D.D. McKee, L.B. Moore, and et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol Cell 6 2000 517 526
85. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D.J. Mangelsdorf, and F.J. Suchy Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor J Biol Chem 276 2001 28857 28865
86. J.L. Boyer, M. Trauner, A. Mennone, C.J. Soroka, S.Y. Cai, T. Moustafa, and et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents Am J Physiol Gastrointest Liver Physiol 290 2006 G1124 G1130
87. T. Claudel, B. Staels, and F. Kuipers The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism Arterioscler Thromb Vasc Biol 25 2005 2020 2030
88. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C.L. Cummins, J.G. McDonald, and et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis Cell Metab 2 2005 217 225
89. M. Watanabe, S.M. Houten, L. Wang, A. Moschetta, D.J. Mangelsdorf, R.A. Heyman, and et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c J Clin Invest 113 2004 1408 1418
90. L. Wang, J. Liu, P. Saha, J. Huang, L. Chan, B. Spiegelman, and et al. The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes Cell Metab 2 2005 227 238
91. L. Wang, J. Huang, P. Saha, R.N. Kulkarni, M. Hu, Y. Kim, and et al. Orphan receptor small heterodimer partner is an important mediator of glucose homeostasis Mol Endocrinol 20 2006 2671 2681
92. M.J. Potthoff, S.A. Kliewer, and D.J. Mangelsdorf Endocrine fibroblast growth factors 15/19 and 21: from feast to famine Genes Dev 26 2012 312 324
93. C. Cicione, C. Degirolamo, and A. Moschetta Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver Hepatology 56 2012 2404 2411
94. T. Inagaki, P. Dutchak, G. Zhao, X. Ding, L. Gautron, V. Parameswara, and et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21 Cell Metab 5 2007 415 425
95. B.M. Owen, D.J. Mangelsdorf, and S.A. Kliewer Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21 Trends Endocrinol Metab 26 2015 22 29
96. S. Bhatnagar, H.A. Damron, and F.B. Hillgartner Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis J Biol Chem 284 2009 10023 10033
97. S. Kir, S.A. Beddow, V.T. Samuel, P. Miller, S.F. Previs, K. Suino-Powell, and et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis Science 331 2011 1621 1624
98. M.J. Potthoff, J. Boney-Montoya, M. Choi, T. He, N.E. Sunny, S. Satapati, and et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway Cell Metab 13 2011 729 738
99. I. Kim, S.H. Ahn, T. Inagaki, M. Choi, S. Ito, G.L. Guo, and et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine J Lipid Res 48 2007 2664 2672
100. S. Modica, M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, N. Celli, and et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis Gastroenterology 142 2012 355 365
101. S. Li, D.D. Hsu, B. Li, X. Luo, N. Alderson, L. Qiao, and et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis Cell Metab 20 2014 320 332
102. M.K. Badman, P. Pissios, A.R. Kennedy, G. Koukos, J.S. Flier, and E. Maratos-Flier Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states Cell Metab 5 2007 426 437
103. M.D. Chau, J. Gao, Q. Yang, Z. Wu, and J. Gromada Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway Proc Natl Acad Sci U S A 107 2010 12553 12558
104. K.R. Markan, M.C. Naber, M.K. Ameka, M.D. Anderegg, D.J. Mangelsdorf, S.A. Kliewer, and et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding Diabetes 63 2014 4057 4063
105. M.J. Potthoff, T. Inagaki, S. Satapati, X. Ding, T. He, R. Goetz, and et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response Proc Natl Acad Sci U S A 106 2009 10853 10858
106. W.L. Holland, A.C. Adams, J.T. Brozinick, H.H. Bui, Y. Miyauchi, C.M. Kusminski, and et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice Cell Metab 17 2013 790 797
107. Z. Lin, H. Tian, K.S. Lam, S. Lin, R.C. Hoo, M. Konishi, and et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice Cell Metab 17 2013 779 789
108. R. Pellicciari, S. Fiorucci, E. Camaioni, C. Clerici, G. Costantino, P.R. Maloney, and et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity J Med Chem 45 2002 3569 3572
109. E. Hambruch, S. Miyazaki-Anzai, U. Hahn, S. Matysik, A. Boettcher, S. Perovic-Ottstadt, and et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice J Pharmacol Exp Ther 343 2012 556 567
110. B. Flatt, R. Martin, T.L. Wang, P. Mahaney, B. Murphy, X.H. Gu, and et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) J Med Chem 52 2009 904 907
111. S.M. Soisson, G. Parthasarathy, A.D. Adams, S. Sahoo, A. Sitlani, C. Sparrow, and et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation Proc Natl Acad Sci U S A 105 2008 5337 5342
112. J.Y. Bass, J.A. Caravella, L. Chen, K.L. Creech, D.N. Deaton, K.P. Madauss, and et al. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene Bioorg Med Chem Lett 21 2011 1206 1213
113. G.M. Hirschfield, A. Mason, V. Luketic, K. Lindor, S. Gordon, M. Mayo, and et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid Gastroenterology 2015 [Epub ahead of print]
114. F.G. Schaap, M. Trauner, and P.L. Jansen Bile acid receptors as targets for drug development Nat Rev Gastroenterol Hepatol 11 2014 55 67
115. U. Beuers, A.E. Kremer, R. Bolier, and R.P. Elferink Pruritus in cholestasis: facts and fiction Hepatology 60 2014 399 407
116. J. Luo, B. Ko, M. Elliott, M. Zhou, D.A. Lindhout, V. Phung, and et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases Sci Transl Med 6 2014 247ra100
117. K. Nicholes, S. Guillet, E. Tomlinson, K. Hillan, B. Wright, G.D. Frantz, and et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice Am J Pathol 160 2002 2295 2307
118. T. Maruyama, Y. Miyamoto, T. Nakamura, Y. Tamai, H. Okada, E. Sugiyama, and et al. Identification of membrane-type receptor for bile acids (M-BAR) Biochem Biophys Res Commun 298 2002 714 719
119. H. Sato, A. Macchiarulo, C. Thomas, A. Gioiello, M. Une, A.F. Hofmann, and et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies J Med Chem 51 2008 1831 1841
120. Y. Kawamata, R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, and et al. A G protein-coupled receptor responsive to bile acids J Biol Chem 278 2003 9435 9440
121. T. Maruyama, K. Tanaka, J. Suzuki, H. Miyoshi, N. Harada, T. Nakamura, and et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice J Endocrinol 191 2006 197 205
122. V. Keitel, K. Cupisti, C. Ullmer, W.T. Knoefel, R. Kubitz, and D. Haussinger The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders Hepatology 50 2009 861 870
123. G. Vassileva, A. Golovko, L. Markowitz, S.J. Abbondanzo, M. Zeng, S. Yang, and et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation Biochem J 398 2006 423 430
124. V. Keitel, M. Donner, S. Winandy, R. Kubitz, and D. Haussinger Expression and function of the bile acid receptor TGR5 in Kupffer cells Biochem Biophys Res Commun 372 2008 78 84
125. V. Keitel, R. Reinehr, P. Gatsios, C. Rupprecht, B. Gorg, O. Selbach, and et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells Hepatology 45 2007 695 704
126. V. Keitel, C. Ullmer, and D. Haussinger The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes Biol Chem 391 2010 785 789
127. Y.D. Wang, W.D. Chen, D. Yu, B.M. Forman, and W. Huang The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice Hepatology 54 2011 1421 1432
128. T.W. Pols, M. Nomura, T. Harach, G. Lo Sasso, M.H. Oosterveer, C. Thomas, and et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading Cell Metab 14 2011 747 757
129. Y.D. Wang, W.D. Chen, D. Yu, B.M. Forman, and W. Huang The G-protein coupled bile acid receptor Gpbar1 (TGR5) negatively regulates hepatic inflammatory response through antagonizing Nuclear Factor kappaB Hepatology 54 2011 1421 1432
130. S. Cipriani, A. Mencarelli, M.G. Chini, E. Distrutti, B. Renga, G. Bifulco, and et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis PLoS One 6 2011 e25637
131. F. Alemi, D.P. Poole, J. Chiu, K. Schoonjans, F. Cattaruzza, J.R. Grider, and et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice Gastroenterology 144 2013 145 154
132. D.P. Poole, C. Godfrey, F. Cattaruzza, G.S. Cottrell, J.G. Kirkland, J.C. Pelayo, and et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system Neurogastroenterol Motil 22 2010 814 825
133. J.B. Ward, M.S. Mroz, and S.J. Keely The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon Neurogastroenterol Motil 25 2013 708 711
134. S. Rajagopal, D.P. Kumar, S. Mahavadi, S. Bhattacharya, R. Zhou, C.U. Corvera, and et al. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway Am J Physiol Gastrointest Liver Physiol 304 2013 G527 G535
135. N. Pean, I. Doignon, I. Garcin, A. Besnard, B. Julien, B. Liu, and et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice Hepatology 58 2013 1451 1460
136. B. Lavoie, O.B. Balemba, C. Godfrey, C.A. Watson, G. Vassileva, C.U. Corvera, and et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels J Physiol 588 2010 3295 3305
137. I. Doignon, B. Julien, V. Serriere-Lanneau, I. Garcin, G. Alonso, A. Nicou, and et al. Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis J Hepatol 54 2011 481 488
138. J.R. Hov, V. Keitel, J.K. Laerdahl, L. Spomer, E. Ellinghaus, A. ElSharawy, and et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis PLoS One 5 2010 e12403
139. J.R. Hov, V. Keitel, E. Schrumpf, D. Haussinger, and T.H. Karlsen TGR5 sequence variation in primary sclerosing cholangitis Dig Dis 29 2011 78 84
140. A. Baghdasaryan, T. Claudel, J. Gumhold, D. Silbert, L. Adorini, A. Roda, and et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO output Hepatology 54 2011 1303 1312
141. A. Baghdasaryan, P. Jha, M. Müller, L. Agostinelli, S. Saccomanno, N. Auer, and et al. Protective role of membrane bile acid receptor TGR5 (GPBAR1) in DDC-induced sclerosing cholngitis in mice J Hepatol 60 2014 S197 S198
142. G. Perides, J.M. Laukkarinen, G. Vassileva, and M.L. Steer Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1 Gastroenterology 138 2010 715 725
143. V. Keitel, B. Gorg, H.J. Bidmon, I. Zemtsova, L. Spomer, K. Zilles, and et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain Glia 58 2010 1794 1805
144. M.S. Desai, Z. Shabier, M. Taylor, F. Lam, S. Thevananther, A. Kosters, and et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis Hepatology 51 2010 2097 2107
145. F. Alemi, E. Kwon, D.P. Poole, T. Lieu, V. Lyo, F. Cattaruzza, and et al. The TGR5 receptor mediates bile acid-induced itch and analgesia J Clin Invest 123 2013 1513 1530
146. T. Lieu, G. Jayaweera, P. Zhao, D.P. Poole, D. Jensen, M. Grace, and et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice Gastroenterology 147 2014 1417 1428
147. J.I. Yang, J.H. Yoon, S.J. Myung, G.Y. Gwak, W. Kim, G.E. Chung, and et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes Biochem Biophys Res Commun 361 2007 156 161
148. V. Keitel, M. Reich, A. Sommerfeld, S. Kluge, R. Kubitz, and D. Häussinger The bile acid receptor TGR5 promotes cholangiocyte proliferation through a cSRC-EGFR-ERK signaling pathway J Hepatol 58 2013 S574 S575
149. W. Cao, W. Tian, J. Hong, D. Li, R. Tavares, L. Noble, and et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma Am J Physiol Gastrointest Liver Physiol 304 2013 G322 G327
150. M. Pawlak, P. Lefebvre, and B. Staels Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease J Hepatol 62 2015 720 733
151. M. Pawlak, E. Bauge, W. Bourguet, K. De Bosscher, F. Lalloyer, A. Tailleux, and et al. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice Hepatology 60 2014 1593 1606
152. T. Kok, H. Wolters, V.W. Bloks, R. Havinga, P.L. Jansen, B. Staels, and et al. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse Gastroenterology 124 2003 160 171
153. T. Kok, V.W. Bloks, H. Wolters, R. Havinga, P.L. Jansen, B. Staels, and et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice Biochem J 369 2003 539 547
154. T. Matsumoto, H. Miyazaki, Y. Nakahashi, J. Hirohara, T. Seki, K. Inoue, and et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate Hepatol Res 30 2004 125 136
155. J. Shoda, Y. Inada, A. Tsuji, H. Kusama, T. Ueda, T. Ikegami, and et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4 J Lipid Res 45 2004 1813 1825
156. A. Honda, T. Ikegami, M. Nakamuta, T. Miyazaki, J. Iwamoto, T. Hirayama, and et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid Hepatology 57 2013 1931 1941
157. N.S. Ghonem, D.N. Assis, and J.L. Boyer On fibrates and cholestasis: a review Hepatology 2015 10.1002/hep.27744 [Epub ahead of print]
158. F.J. Cuperus, E. Halilbasic, and M. Trauner Fibrate treatment for primary biliary cirrhosis Curr Opin Gastroenterol 30 2014 279 286
159. Y. Zhang, K. Chen, W. Dai, Y. Xia, F. Wang, M. Shen, and et al. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: a meta-analysis Hepatol Res 45 2015 48 58
160. S. Lens, M. Leoz, L. Nazal, M. Bruguera, and A. Pares Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid Liver Int 34 2014 197 203
161. S.A. Kliewer, and T.M. Willson Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor J Lipid Res 43 2002 359 364
162. G. Bertilsson, J. Heidrich, K. Svensson, M. Asman, L. Jendeberg, M. Sydow-Backman, and et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction Proc Natl Acad Sci U S A 95 1998 12208 12213
163. J.L. Staudinger, B. Goodwin, S.A. Jones, D. Hawkins-Brown, K.I. MacKenzie, A. LaTour, and et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity Proc Natl Acad Sci U S A 98 2001 3369 3374
164. H.L. Fang, S.C. Strom, E. Ellis, Z. Duanmu, J. Fu, Z. Duniec-Dmuchowski, and et al. Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor J Pharmacol Exp Ther 323 2007 586 598
165. D. Gardner-Stephen, J.M. Heydel, A. Goyal, Y. Lu, W. Xie, T. Lindblom, and et al. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression Drug Metab Dispos 32 2004 340 347
166. R. van Dijk, A.E. Kremer, W. Smit, B. van den Elzen, T. van Gulik, D. Gouma, J.S. Lameris, and et al. Characterization and treatment of persistent hepatocellular secretory failure Liver Int 2014 10.1111/liv.12603 [Epub ahead of print]
167. A. Geick, M. Eichelbaum, and O. Burk Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin J Biol Chem 276 2001 14581 14587
168. H.R. Kast, B. Goodwin, P.T. Tarr, S.A. Jones, A.M. Anisfeld, C.M. Stoltz, and et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor J Biol Chem 277 2002 2908 2915
169. S. Teng, V. Jekerle, and M. Piquette-Miller Induction of ABCC3 (MRP3) by pregnane X receptor activators Drug Metab Dispos 31 2003 1296 1299
170. C. Stedman, C. Liddle, S. Coulter, J. Sonoda, J.G. Alvarez, R.M. Evans, and et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis Proc Natl Acad Sci U S A 103 2006 11323 11328
171. C.A. Stedman, C. Liddle, S.A. Coulter, J. Sonoda, J.G. Alvarez, D.D. Moore, and et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury Proc Natl Acad Sci U S A 102 2005 2063 2068
172. S. Teng, and M. Piquette-Miller Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis Br J Pharmacol 151 2007 367 376
173. L. Bachs, A. Pares, M. Elena, C. Piera, and J. Rodes Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis Lancet 1 1989 574 576
174. L. Bachs, A. Pares, M. Elena, C. Piera, and J. Rodes Effects of long-term rifampicin administration in primary biliary cirrhosis Gastroenterology 102 1992 2077 2080
175. K. Dilger, A. Denk, M.H. Heeg, and U. Beuers No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis Hepatology 41 2005 595 602
176. S. Khurana, and P. Singh Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials Liver Int 26 2006 943 948
177. M.P. Manns, M. Woynarowski, W. Kreisel, Y. Lurie, C. Rust, E. Zuckerman, and et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis Gastroenterology 139 2010 1198 1206
178. Y. Lu, Z. Zhang, X. Xiong, X. Wang, J. Li, G. Shi, and et al. Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid x receptor Gastroenterology 143 2012 1630 1640
179. D. Jung, A.C. Fantin, U. Scheurer, M. Fried, and G.A. Kullak-Ublick Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor Gut 53 2004 78 84
180. J.J. Eloranta, and G.A. Kullak-Ublick Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism Arch Biochem Biophys 433 2005 397 412
181. J.J. Eloranta, D. Jung, and G.A. Kullak-Ublick The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism Mol Endocrinol 20 2006 65 79
182. F. Arenas, I. Hervias, M. Uriz, R. Joplin, J. Prieto, and J.F. Medina Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells J Clin Invest 118 2008 695 709
183. M. Leuschner, K.P. Maier, J. Schlichting, S. Strahl, G. Herrmann, H.H. Dahm, and et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial Gastroenterology 117 1999 918 925
184. H. Rautiainen, P. Karkkainen, A.L. Karvonen, H. Nurmi, P. Pikkarainen, H. Nuutinen, and et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial Hepatology 41 2005 747 752
185. P. Angulo, R.A. Jorgensen, J.C. Keach, E.R. Dickson, C. Smith, and K.D. Lindor Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid Hepatology 31 2000 318 323
186. N. Rabahi, Y. Chretien, F. Gaouar, D. Wendum, L. Serfaty, O. Chazouilleres, and et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone Gastroenterol Clin Biol 34 2010 283 287
187. W. Hempfling, F. Grunhage, K. Dilger, C. Reichel, U. Beuers, and T. Sauerbruch Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis Hepatology 38 2003 196 202
188. J.R. Mora, M. Iwata, and U.H. von Andrian Vitamin effects on the immune system: vitamins A and D take centre stage Nat Rev Immunol 8 2008 685 698
189. E. D'Aldebert, M.J. Biyeyeme Bi Mve, M. Mergey, D. Wendum, D. Firrincieli, A. Coilly, and et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium Gastroenterology 136 2009 1435 1443
190. J. Cheng, Z.Z. Fang, J.H. Kim, K.W. Krausz, N. Tanaka, J.Y. Chiang, and et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice J Lipid Res 55 2014 455 465
191. D.R. Schmidt, S.R. Holmstrom, K. Fon Tacer, A.L. Bookout, S.A. Kliewer, and D.J. Mangelsdorf Regulation of bile acid synthesis by fat-soluble vitamins A and D J Biol Chem 285 2010 14486 14494
192. S. Abramovitch, L. Dahan-Bachar, E. Sharvit, Y. Weisman, A. Ben Tov, E. Brazowski, and S. Reif Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats Gut 60 2011 1728 1737
193. K. Hochrath, C.S. Stokes, J. Geisel, M.J. Pollheimer, P. Fickert, S. Dooley, and et al. Vitamin D modulates biliary fibrosis in ABCB4-deficient mice Hepatol Int 8 2014 443 452
194. N. Ding, R.T. Yu, N. Subramaniam, M.H. Sherman, C. Wilson, R. Rao, and et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response Cell 153 2013 601 613
195. B. Hagenbuch, and P. Dawson The sodium bile salt cotransport family SLC10 Pflugers Arch 447 2004 566 570
196. J.R. Walters, A.M. Tasleem, O.S. Omer, W.G. Brydon, T. Dew, and C.W. le Roux A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis Clin Gastroenterol Hepatol 7 2009 1189 1194
197. A.C. Mauricio, M. Slawik, D. Heitzmann, T. von Hahn, R. Warth, M. Bleich, and et al. Deoxycholic acid (DOC) affects the transport properties of distal colon Pflugers Arch 439 2000 532 540
198. T. Harach, T.W. Pols, M. Nomura, A. Maida, M. Watanabe, J. Auwerx, and et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins Sci Rep 2 2012 430
199. M.J. Potthoff, A. Potts, T. He, J.A. Duarte, R. Taussig, D.J. Mangelsdorf, and et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice Am J Physiol Gastrointest Liver Physiol 304 2013 G371 G380
200. M. Trauner, E. Halilbasic, A. Baghdasaryan, T. Moustafa, E. Krones, P. Fickert, and et al. Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment Dig Dis 30 2012 39 47